8-K current report · filed Aug 12, 2026

MAXCYTE, INC. (MXCT) 8-K Current Report: August 12, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.1#2MXCT overview

Short answer

MAXCYTE, INC. (MXCT) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.1#2 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026 announced August 12, 2026.

MAXCYTE, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced August 12, 2026
  • Full financial results and management commentary furnished in Exhibit 99.1
  • Disclosure furnished, not filed under Exchange Act Section 18 liability provisions

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation posted August 12, 2026 for investor communications and conferences
  • Exhibit 99.2 contains management’s latest corporate messaging and strategy context
  • Disclosure furnished under Regulation FD, not filed under Section 18 liability standards

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $7.3M, down 15% YoY; core revenue $6.5M, down 21%, signaling continued operating softness
  • SPL revenue rose to $0.8M from $0.3M, driven by royalties up 150% to $0.8M
  • Gross margin fell to 77% from 82%, while adjusted core margin declined to 77% from 83%
  • Net loss improved to $8.9M from $12.4M as operating expenses fell to $15.8M from $21.2M
  • 2026 guidance reiterated at $30M-$32M revenue and at least $130.5M ending cash, excluding further buybacks

Item EX-99.1#2 · Exhibit EX-99.1

  • Corporate presentation updates investors on MaxCyte’s platform, customer pipeline, financial profile, and growth strategy as of August 2026
  • Core revenue $12.7M, down 23% year-to-date, signaling continued weakness despite SPL-related revenue growth of 71% to $4.2M
  • Total revenue $16.9M, down 10% year-to-date, with net loss $13.6M and EBITDA loss $14.4M
  • Cash, cash equivalents, and investments $142M, supporting stated plans to fund operations and pursue growth investments
  • 29 SPL partners, 12 active clinical programs, and approximately $110M of precommercial milestone potential underpin longer-term upside tied to partner development success

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MAXCYTE, INC. 8-K filings

Get the next MXCT 8-K as it lands

Follow MXCT for push alerts, or ask the research agent what this filing means.